Mirum Pharmaceuticals (MIRM) closed at $94.42 on November 10, 2026, up 1.3% from the previous close, on volume of 588,136 shares (30-day average 723,861).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Mirum succeeds in second late-stage trial for hepatitis D therapy
Seeking Alpha News (Tue, 10-Nov 1:26 PM ET)
Mirum’s Strong Bre-lovitug Profile and Commercial Potential Support a Buy Rating
TipRanks (Tue, 10-Nov 8:05 AM ET)
Mirum Pharmaceuticals Reports Positive Phase 3 Brelovitug Results
TipRanks (Tue, 10-Nov 7:58 AM ET)
Business Wire (Tue, 10-Nov 7:30 AM ET)
TipRanks (Tue, 10-Nov 6:36 AM ET)
TipRanks (Fri, 6-Nov 2:15 AM ET)
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Wire (Tue, 3-Nov 4:01 PM ET)
Business Wire (Mon, 2-Nov 8:02 AM ET)
Business Wire (Tue, 27-Oct 4:01 PM ET)
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Mirum Pharmaceuticals trades on the NASDAQ stock market under the symbol MIRM.
As of November 10, 2026, MIRM stock price climbed to $94.42 with 588,136 million shares trading.
MIRM has a beta of 0.64, meaning it tends to be less sensitive to market movements. MIRM has a correlation of 0.03 to the broad based SPY ETF.
MIRM has a market cap of $5.76 billion. This is considered a Mid Cap stock.
Last quarter Mirum Pharmaceuticals reported $186 million in Revenue and -$.87 earnings per share. This beat revenue expectation by $8 million and missed earnings estimates by -$.43.
In the last 3 years, MIRM traded as high as $130.00 and as low as $23.14.
The top ETF exchange traded funds that MIRM belongs to (by Net Assets): VTI, XBI, IWM, VB, VBK.
MIRM has outperformed the market in the last year with a price return of +38.6% while the SPY ETF gained +12.9%. However, in the short term, MIRM had mixed performance relative to the market. It has underperformed in the last 3 months, returning -6.2% vs -2.8% return in SPY. But in the last 2 weeks, MIRM shares have fared better than the market returning +13.4% compared to SPY -2.0%.
MIRM support price is $90.07 and resistance is $96.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIRM shares will trade within this expected range on the day.
